Giovanna Ciocca
Dermatology · Miami, FLNPI 1285689232
Payments from drug & device makers
Across 2,346 payments — averaging $1373.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.4M
- Eli Lilly$669K
- Incyte Corporation$561K
- Pfizer$259K
- Dermavant Sciences, Inc.$109K
- Regeneron Healthcare Solutions, Inc.$56K
- plus $176K from 43 others
Across 5 payments — averaging $2737.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Almirall LLC$14K
What the payments were for
- Consulting fees$47,56021%
- Speaking & faculty fees$122,51755%
- Travel & lodging$18,0548%
- Food & beverage$33,61415%
- Education$4170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,222,957 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $190,728 |
| Dupixent PenDupilumab | 20 | $73,544 |
| OtezlaApremilast | 11 | $49,872 |
| OpzeluraRuxolitinib Phosphate | 11 | $21,161 |
| Tacrolimus | 77 | $10,114 |
| Mometasone Furoate | 263 | $4,905 |
| Pimecrolimus | 13 | $4,362 |
| Ketoconazole | 276 | $3,916 |
| Clobetasol Propionate | 28 | $2,350 |
| Metronidazole | 41 | $1,958 |
| Imiquimod | 61 | $1,889 |
| Ammonium Lactate | 101 | $1,506 |
| Mupirocin | 225 | $1,412 |
| Triamcinolone Acetonide | 198 | $1,352 |
| Clindamycin Phosphate | 65 | $1,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,393,186 | $49,87211 claims |
| Incyte CorporationOpzelura | $560,703 | $21,16111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miami
- Hector Wiltz JrMiami$6.4M
- Francisco KerdelMiami$5.1M
- Jill WaibelMiami$4.3M
- Gil YosipovitchMiami$3.7M
- Mercedes GonzalezMiami$3.6M
- David RodriguezMiami$3M
- Hadar Lev-TovMiami$2.5M
- Leslie BaumannMiami$2.3M
- Mojgan HosseinipourMiami$1.6M
- Robert KirsnerMiami$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.